Tuberculosis
Definition
·
Tuberculosis remains a leading
cause of infectious morbidity and mortality worldwide.
·
World Health Organization (WHO)
called tuberculosis a "global emergency, 1993"
·
About 8 million new cases of
tuberculosis each year.
·
Miliary tuberculosis is a
systemic version of TB affecting many organ systems due to hematogenous spread.
Etiology
·
Mycobacterium tuberculosis—the major etiologic agent worldwide; humans are the sole reservoir
·
M. bovis—transmitted from milk of infected cows; rare since
institution of pasteurization
·
M. africanum—rare; only in Africa
Risk Factors
- Occupational: healthcare workers—airborne transmission,
infection from extrapulmonary disease such as draining an abscess,
autopsies; embalmers—from body fluids generating infectious aerosols
- Contact with infected person
- Location of birth: Asia, Africa, Latin
America
- HIV infection
- Residence in a long-term care facility
- Immunosuppressive therapy
- Tuberculosis infection: increases likelihood of developing
active disease within two years
- Low income, medically underserved individuals
- In areas with a high incidence of TB, exogenous re-infection is
a major cause of recurrence after effective treatment.
Signs and Symptoms
- Asymptomatic—especially from initial infection
- Mild fever, headache, chills, night sweats
- Malaise, fatigue
- Anorexia, weight loss
- Cough—nonproductive or mucopurulent
- Hemoptysis
- Pleuritic chest pain
- Dyspnea
- Adenopathy
- Children—asymptomatic and extrapulmonary manifestations are
more frequent than in adults; look for signs of meningitis, adenopathy
Differential Diagnosis
- Bacterial pneumonia
- Other nontubercular mycobacterial infections
- Lymphomas
- Sarcoidosis
- Lung abscess
Drug Therapies
Standard antibiotics for
tuberculosis include:
- Isoniazid—adults 5 mg/kg/day, children 10 to 20 mg/kg/day, 300
mg maximum for both; side effects: hepatitis (risk increased with alcohol
consumption), peripheral neuropathy, rash, fever; additional drug
interactions and toxicity for patients with HIV
- Rifampin—adults 10 mg/kg/day, maximum 600 mg/day, children 10
to 20 mg/kg/day; side effects: gastrointestinal upset, hepatitis, orange
discoloration of body fluids (and contact lenses); additional drug
interactions and toxicity for patients with HIV
- Pyrazinamide—15 to 30 mg/kg/day, 2 g maximum; side effects:
hepatitis, hyperuricemia possibly with polyarthralgias (both reduced by
concurrent rifampin administration)
- Ethambutol—least potent against M. ; 15 to
25 mg/kg/day for 2 months, then reduce to 15 mg/kg/day; side effects: retrobulbar
optic neuritis and color perception problems, avoid with children
- Streptomycin—used least often because of toxicity;
intramuscular or intravenous administration of 10 to 15 mg/kg/day, maximum
1 g/day, up to 5 times per week for adults, 20 to 40 mg/kg/day with 1
g/day maximum for children; side effects: ototoxicity (both hearing loss
and vestibular dysfunction), nephrotoxicity, teratogenic
- Pyridoxine (vitamin B6) added to regimen
particularly in populations at risk for vitamin deficiency (e.g., malnourished,
alcoholics, elderly, pregnant and nursing mothers) or at risk for
neuropathy (diabetics, HIV, chronic renal failure)
Experimental drugs:
- Rifapentine—longer acting, allowing dosing twice a week
- Fluoroquinolones (e.g., ciprofloxacin)—antibacterial;
concentrations higher in respiratory secretions than in serum; well
tolerated, but insufficient data to use as standard treatment; less
effective with HIV
- Rifabutin—as effective as rifampin with concurrent HIV, but
reduces time to sputum conversion; 150 mg/day associated with fewest
adverse effects; possible role with multidrug resistance
TUBERCULOSIS
THERAPY
Based on antitubercular activity
1.
Tuberculocidal
agents – Isoniazid, Rifampicin, Streptomycin, pyrazinamide, capreomycin,
Kanamycin, Ciprofloxacin.
2.
Tuberculostatic
agents – Ethambutol, ethionamide, thiacetazone, cycloserine, PAS.
First line drugs
Isoniazid (INH) – Tuberculocidal for rapidly multiplying
bacilli but static for resting bacilli.
INH destroys:
a) intracellular bacilli as it penetrates into the
cells, and
b) Bacilli multiplying in the walls of the
cavities.
Thus it is effective against both intra and extracellular organisms.If
used alone, mycobacteria develop resistance.
Mechanism of action: INH inhibits the synthesis of mycolic acids which
is an important component of the mycobacterial cell wall.
Pharmacokinetics: INH is completely absorbed orally, penetrates all
tissues, tubercular cavities, necrotic tissues and CSF. It is metabolised by
acetylation. Metabolites are excreted in urine.
ADRs: Peripheral neuritis (due to interference with utilization and
increased excretion of pyridoxine) can be avoided by giving prophylactic
pyridoxine (10 – 50 mg) with INH.
Hepatitis, CNS toxicity, anorexia etc.
Rifampicin – Antibiotic obtained from Streptomyces mediterranei.
The other rifamycins are rifabutin and rifapentine.
Rifampicin is bactericidal to M.tuberculosis, M.leprae and atypical
mycobacteria. Also inhibits, most Gram +ve and –ve bacteria like Staph.aureus,
N.meningitidis, E.coli, Proteus, Pseudomonas and legionella.
Antitubercular action: Only drug acts on persisters; acts on both intra
and extracellular organisms & is effective against TB bacilli resistant to
other drugs.
MOA: Rifampicin binds to DNA dependent RNA polymerase and inhibits RNA
synthesis in the bacteria.
Pharmacokinetics: has good tissue penetrability – reaches caseous
material, cavities and CSF; It also appears in saliva, tears, sweat.
It is a microsomal enzyme inducer.
ADRs: Skin rashes, diarrhoea, nephritis & hepatotoxicity.
It stains the secretions including tears, saliva and sweat orange red.
Use:
1. TB and atypical mycobacterial infections.
2. Leprosy
3. Prophylaxis of H.influenza and meningococcal
meningitis
4. Resistant staphylococcal infections.
5. Brucellosis – Rifampicin 600 – 900 mg+ Doxy 200
mg daily for 6 weeks.
6. To eradicate carrier state – rifampin
eradicates the nasal carrier state of N.meningitidis, H.influenza and S.aureus
– 600 mg BD for 2 days.
Rifubutin: similar to Rifampicin, may be used in TB pts with AIDS who
are receiving antiviral drugs.
Rifapentine – analog of Rifampicin.
Pyrazinamide: Tuberculocidal,
MOA not known.
It is effective against intracellular bacilli.
ADRs: Hepatotoxicity
Hyperuricaemia – due to ↓excretion of uric acid may result in gouty
arthritis.
Arthralgia, vomiting etc.
Streptomycin: Tuberculocidal, acts against extracellular
organisms due to poor penetrating power.
Second line drugs
Ethambutol: Tuberculostatic, acts on fast multiplying
bacilli in the cavities. Also effective against atypical mycobacteria.
It inhibits the incorporation of mycolic acids into the mycobacterial
cell wall.
Optic neuritis resulting in ↓ visual acuity and inability to
differentiate red from green is an important ADR which needs withdrawal of the
drug. Colour vision should be monitored during treatment.
Anorexia, headache, fever, allergic reactions.
Thiacetazone: Tuberculostatic with low efficacy.
It delays the development of resistance to other drugs.
ADRs: Hepatotoxicity, dermatitis, GI side effects.
Ethionamide: Tuberculostatic, effective against both intra
and extracellular organisms.
It is also effective in atypical mycobacteria.
ADRs: Anorexia, metallic taste in the mouth, hepatitis, peripheral
neuritis.
Ethionamide is a secondary agent used only when primary drugs are
ineffective.
Para-aminosalicylic acid (PAS): related to sulfonamides is tuberculostatic.
GI effects like nausea, anorexia & epigastric pain and diarrhoea
make it poorly tolerated drug.
Rarely used.
Other second line drugs
Amikacin, kanamycin and
capreomycin – They are oto and
nephrotoxic and are used only in resistant cases.
Amikacin is effective against atypical mycobacteria.
Cycloserine – antibiotic that inhibits cell wall synthesis,
is tuberculostatic, also effective against some gram-positive organisms.
It causes CNS toxicity including headache, tremors, psychosis and
sometimes seizures. It is used only in resistant TB.
Fluoroquinolones – Ciprofloxacin, ofloxacin and sparfloxacin
inhibit TB bacilli and atypical mycobacteria.
They are useful in multidrug resistant TB in combination with other
drugs.
Treatment
of TB
A combination of trt is given to
- delay the development of resistance
- reduce toxicity
- shorten the course of trt.
Chemotherapy is given in 2 phases
–
-
First
phase – initial, intensive phase of 1 – 3 months duration aimed at killing as
many as possible.
-
Second
phase – continuation phase to destroy the dormant or persisters – duration 6 –
9 months.
Short-term regimens
Directly Observed Treatment (DOT)
is a strategy that is found to
be effective & is recommended throughout the world.
INH + R + Z + E/S daily for 2 months
Followed by
INH + R daily for 4 months.
Role of glucocorticoids:
As steroids depress host defense mechanisms, they should be used only in
conditions like TB meningitis, miliary TB, pleural effusion, renal TB.
Steroids suppress inflammatory reaction which can lead to extensive
fibrosis and damage.
Rifampicin – 600 mg
INH - 300 mg
Pyrazinamide – 2000 mg
Ethambutol - 1500 mg
Streptomycin – 1 gm